From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation

Press/Media

Description

A range of articles on the titled designs

Period	19 Dec 2022 → 20 Dec 2022

Title 浸大研製「玻璃骨」適配子藥物
Country/Territory Hong Kong
Date 20/12/22
Producer/Author 文匯報
Persons Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG
Title 分子標靶治玻璃骨新療法浸大開發適配子藥降中風危險
Country/Territory Hong Kong
Date 20/12/22
Producer/Author 信報
Persons Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG
Title 浸大研發新藥治骨質疏鬆不增心血管病風險
Country/Territory Hong Kong
Date 20/12/22
Producer/Author Skypost晴報
Persons Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG
Title 浸大研新藥治骨質疏鬆症獲美國認證　比舊藥減引發心血管疾病機率
Country/Territory Hong Kong
Date 19/12/22
Persons Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG

Title	浸大研製「玻璃骨」適配子藥物
Country/Territory	Hong Kong
Date	20/12/22
Producer/Author	文匯報
Persons	Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG

Title	分子標靶治玻璃骨新療法浸大開發適配子藥降中風危險
Country/Territory	Hong Kong
Date	20/12/22
Producer/Author	信報
Persons	Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG

Title	浸大研發新藥治骨質疏鬆不增心血管病風險
Country/Territory	Hong Kong
Date	20/12/22
Producer/Author	Skypost晴報
Persons	Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG

Title	浸大研新藥治骨質疏鬆症獲美國認證　比舊藥減引發心血管疾病機率
Country/Territory	Hong Kong
Date	19/12/22
Persons	Yuanyuan YU, Ge ZHANG, Aiping LYU, Luyao WANG